Kailera Therapeutics raises $400M to advance next-generation obesity therapies... and more - Life Science Headlines October 10, 2024
Cari Kraft
Top 10% LinkedIn Recruiter, Medical Device Recruiter, Pharmaceutical Recruiter, Biotechnology Recruiter - ckraft@jacobsmgt.com; Career Igniter, Publisher HS&M
Kailera Therapeutics raises $400M to advance next-generation obesity therapies Boston, MA , October 1, 2024 (Globe Newswire) -- Kailera Therapeutics has launched as a clinical-stage biopharmaceutical company focused on obesity treatments, backed by $400 million in Series A financing.
Halda Therapeutics appoints Christian Schade as President and CEO to advance novel cancer therapies New Haven, CT, October 1, 2024 (Business Wire) -- Halda Therapeutics has appointed Christian Schade as President and CEO, enhancing its leadership as it develops its novel RIPTAC™ cancer therapies.
CeriBell upsizes IPO, targets $578M valuation Fargo, ND, October 9, 2024 (Reuters) -- CeriBell is aiming for a valuation of up to $578.3 million, aiming to raise $180 million by offering approximately 10.6 million shares at $16 to $17 each.
Keith Dionne, Ph.D. Appointed CEO of Luxa Biotechnology Fort Lee, NJ, October 1, 2024 (Business Wire) -- Dr. Keith Dionne has been appointed as the CEO of Luxa Biotechnology, where he will lead the development of a novel RPESC therapy for dry AMD.
ShiraTronics Series B Raises $66M Minneapolis, MN, October 9, 2024 (PR Newswire) -- ShiraTronics secures $66 million in Series B financing to propel the development of its innovative neurostimulation therapy for chronic migraine.
About the Author: Cari Kraft is the CEO of Jacobs Management Group, an Advisory Board Member at Experts OnTap, and the Publisher of Healthcare Sales and Marketing Magazine. Cari and her team specialize in placing top talent with Medical Device, Biotechnology, and Pharmaceutical companies nationwide.